Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyBluecross Idaho IV Tocilizumab Coverage Update | O…
    Ask Trek AI about this page
    ModifiedBluecross IdahoPolicy 5.01.502

    Intravenous Tocilizumab (IV tocilizumab) coverage

    Customize your policy alerts

    Sign up for Bluecross Idaho Policy 5.01.502 alerts

    Get alerted when Policy 5.01.502 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical-benefit coverage, clinical criteria, and prior-authorization expectations for intravenous tocilizumab (including Actemra and listed biosimilars) for specified indications; applies to Blue Cross of Idaho members subject to their member-specific benefit plan.

    Policy Summary
    PayerBluecross Idaho
    PolicyIntravenous Tocilizumab (IV tocilizumab) coverage
    Policy CodePolicy 5.01.502
    Change TypeAdoption with clarifications (TB screening, benefit routing)
    Effective DateJan 1, 2026
    Last ReviewSep 25, 2025
    Next Review DateJan 1, 2026
    Key ActionObtain prior authorization and document TB screening within 6 months, HBV evaluation, and prior therapy failures as required.
    SourceLink
    POLICY UPDATE CHANGES

    Blue Cross of Idaho adopted changes effective 01/01/2026, including a policy statement about subcutaneous formulation and clarifications related to tuberculosis screening.

    New policy added to prescription drug section.

    tocilizumab is to be filled under the pharmacy benefit.

    6Covered indications
    8 mg/kgFDA maintenance dose (adults)
    Within 6 monthsTB screening interval

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≤4 dosesCRS dose limit
    J3262, Q5133, Q5135HCPCS codes

    Coverage Criteria

    inv-01: General medical necessity

    Intravenous tocilizumab may be considered medically necessary when ALL of the general requirements below are met and ONE of the indication-specific criteria is satisfied.

    General requirements: 1) Individual has had an inadequate therapeutic response to at least two (2) covered alternative products for the requested indication (if available) on either pharmacy or medical benefit, OR has a documented contraindication or intolerance to all available covered alternatives; AND 2) Tuberculosis (TB) screening within 6 months prior to initiating therapy confirming no active tuberculosis OR latent TB treated prior to use OR if switching from another targeted immune modulator with no new risk factors TB screening may not be necessary; AND 3) Patient is not at risk for HBV infection OR HBV infection has been ruled out or treatment for HBV infection has been initiated; AND 4) Absence of active infection (including TB and HBV); AND 5) Not used in combination with any other biologic DMARD, targeted synthetic DMARD, or other immunomodulator; AND 6) Not given concurrently with live vaccines.

    inv-02: Rheumatoid Arthritis (RA) - Initial Therapy

    Rheumatoid Arthritis (RA) - covered when ALL of the following are met:

    RA criteria: a) Age ≥18 years with moderately to severely active rheumatoid arthritis; AND b) IV infusion dosage within the FDA labeled maintenance dose of 8 mg/kg every 4 weeks; AND c) Inadequate response to at least a 3-month trial of methotrexate at adequate dosing (e.g., titrated to 20 mg/week); OR d) If intolerance or contraindication to methotrexate, inadequate response/intolerance/contraindication to a 3-month trial of at least one other conventional DMARD.

    inv-03: Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Initial Therapy

    Polyarticular Juvenile Idiopathic Arthritis (PJIA) - covered when ALL of the following are met:

    PJIA criteria: a) Age ≥2 years with moderately to severely active polyarticular juvenile idiopathic arthritis; AND b) Inadequate treatment response, intolerance, or contraindication to a 3-month trial of at least one conventional DMARD; AND c) IV infusion dosage within the FDA labeled maintenance dose: i) patients <30 kg: 10 mg/kg every 4 weeks; ii) patients ≥30 kg: 8 mg/kg every 4 weeks.

    inv-04: Systemic Juvenile Idiopathic Arthritis (SJIA) - Initial Therapy

    Systemic Juvenile Idiopathic Arthritis (SJIA) - covered when ALL of the following are met:

    SJIA criteria: a) Age ≥2 years with active systemic juvenile idiopathic arthritis (Still's disease); AND b) IV infusion dosage within the FDA labeled maintenance dosing: i) patients <30 kg: 12 mg/kg every 2 weeks; ii) patients ≥30 kg: 8 mg/kg every 2 weeks; AND c) Inadequate treatment response to at least a 2-week trial of corticosteroids OR inadequate response to at least a 3-month trial of methotrexate or leflunomide.

    inv-05: Giant Cell Arteritis (GCA) - Initial Therapy

    Giant Cell Arteritis (GCA) - covered when ALL of the following are met:

    GCA criteria: a) Age ≥18 years with giant cell arteritis; AND b) Inadequate treatment response, intolerance, or contraindication to at least a 3-month trial of corticosteroids; AND c) IV infusion dosage within the FDA labeled maintenance dose of 6 mg/kg every 4 weeks.

    inv-06: CAR T–cell induced Cytokine Release Syndrome (CRS) - Initial/Acute Therapy

    Cytokine Release Syndrome (CRS) - covered when ALL of the following are met:

    CRS criteria: a) Age ≥2 years with CAR T cell–induced cytokine release syndrome; AND b) Syndrome is severe or life‑threatening; AND c) IV dosing per FDA: i) patients <30 kg: 12 mg/kg with up to 3 additional doses administered at least 8 hours apart; ii) patients ≥30 kg: 8 mg/kg with up to 3 additional doses administered at least 8 hours apart; total tocilizumab dose should not exceed 800 mg per course; AND d) Tocilizumab for CRS is limited to acute treatment (should not exceed four doses total; continuation/renewal requests for CRS are not allowed).

    inv-07: Castleman's Disease (unicentric or multicentric)

    Castleman's Disease - covered when ALL of the following are met:

    Castleman's criteria: Unicentric: diagnosis of relapsed or refractory unicentric Castleman's disease AND IV tocilizumab used as single‑agent therapy AND individual is HIV negative AND HHV‑8 negative AND IV infusion dosage 8 mg/kg every 4 weeks. Multicentric: diagnosis of multicentric Castleman's disease AND disease has progressed following treatment of relapsed/refractory or progressive disease AND IV tocilizumab used as single‑agent therapy AND IV infusion dosage 8 mg/kg every 2 weeks.

    inv-08: Covered indications and safety criteria

    Coverage aligns with FDA-approved indications and recognized off-label uses per NCCN where specified.

    FDA-approved indications: Tocilizumab (Actemra) FDA‑approved indications include: adult moderately to severely active RA with inadequate response to DMARDs; giant cell arteritis; slowing decline in pulmonary function in SSc‑ILD; patients ≥2 years with active PJIA and SJIA; and CAR T cell‑induced severe or life‑threatening CRS; hospitalized adults with COVID‑19 meeting specified oxygen/ventilation/ECMO criteria.

    See regulatory status

    NCCN-off-label indications: NCCN supports tocilizumab for unicentric and multicentric Castleman's disease as single‑agent subsequent therapy per dosing noted (8 mg/kg every 2 weeks for specified CD uses).

    See off‑label uses

    Safety prerequisites: Patient must not have active infection; evaluate and test for latent TB prior to initiation and consider anti‑TB therapy when indicated; avoid use in active hepatic disease or untreated HBV/HCV; perform baseline and ongoing laboratory monitoring every 4–8 weeks for neutrophils, platelets, lipids, and liver function.

    See safety and monitoring guidance

    IV tocilizumab is investigational for any indication not specifically listed in this policy. The policy enumerates covered uses (including Castleman’s disease, CAR T–cell induced CRS, RA, PJIA, SJIA, and GCA); any request for intravenous tocilizumab outside those listed indications is considered investigational and unsupported by this document.

    Concurrent use of IV tocilizumab with other biologic disease‑modifying antirheumatic drugs (DMARDs) or biologic agents (for example, TNF antagonists, IL‑1 receptor antagonists, anti‑CD20 monoclonal antibodies, or selective costimulation modulators) should be avoided due to the potential for increased immunosuppression and infection risk. Tocilizumab may be used as monotherapy or with nonbiologic DMARDs (e.g., methotrexate, hydroxychloroquine, leflunomide, azathioprine, cyclosporine) per the policy.

    This policy clarifies benefit routing and screening requirements: tocilizumab is to be filled under the pharmacy benefit, and administration/billing guidance should follow the appropriate benefit and place‑of‑service coding. Prior authorization is required for IV tocilizumab to ensure appropriate use. In addition, documentation of tuberculosis screening is required — TB evaluation must be completed and documented as indicated by the policy prior to initiation (see screening clarifications in the policy record).

    For CAR T–cell–induced cytokine release syndrome (CRS), IV tocilizumab is limited to acute treatment only. Continuation or renewal requests for CRS are not allowed, and treatment for CRS should not exceed a total of four doses (dosing per the CRS criteria with up to three additional doses given ≥8 hours apart as specified).

    Safety and effectiveness of tocilizumab have not been established in pediatric patients for conditions other than PJIA, SJIA, or CAR T cell–induced CRS. Specifically, use in children under age 2 has not been studied and is not supported by this policy.

    Initial Therapy Criteria

    inv-39: Initial therapy requirements

    Initial therapy is covered when the general requirements are met and the relevant indication-specific initiation criteria above are satisfied.

    Initial therapy general: See General medical necessity node: prior therapy documentation (inadequate response to required prior therapies or documented contraindication/intolerance), TB screening within 6 months (or treated latent TB), HBV evaluation/treatment status, absence of active infection, not combined with other biologic/targeted DMARDs or immunomodulators, and not administered with live vaccines.

    inv-40: Initiation

    Initiation follows FDA‑labeled indications and recognized compendium uses; ensure appropriate baseline screening and monitoring.

    Initiation: Coverage aligns with FDA‑labeled indications (see list) and NCCN compendium where applicable; document prior inadequate response to recommended prior therapies per indication and complete baseline TB and HBV screening and baseline labs prior to starting therapy.

    Continuation of Treatment

    inv-41: Continuation of Treatment

    Continuation or renewal requests for IV tocilizumab may be considered medically necessary when ALL of the following criteria are met:

    Continuation criteria: 1) Original initiation criteria for the requested indication were previously met; AND 2) There is clinically significant and functionally relevant improvement or stabilization in disease signs and symptoms with tocilizumab; AND 3) Absence of active infection (including TB and HBV); AND 4) Not used in combination with any other biologic DMARD, targeted synthetic DMARD, or other immunomodulator; AND 5) Not given concurrently with live vaccines; AND 6) Dosage is within the FDA labeled maintenance dose; AND 7) Continuation is NOT permitted for cytokine release syndrome (CRS) — CRS is limited to acute dosing (no continuation/renewal allowed; ≤4 total doses).

    inv-42: Ongoing therapy requirements

    Ongoing therapy should include regular monitoring and infection surveillance.

    Monitoring: Laboratory monitoring every 4–8 weeks for neutrophils, platelets, lipids, and liver function during treatment; monitor for signs/symptoms of infection and assess TB/HBV status as clinically indicated.

    Step Therapy and Prior Treatments

    Prior therapy requiredRequired trial duration / details
    At least two (2) covered alternative products for the requested indication (or documented contraindication/intolerance to all available covered alternatives)
    Generally requires inadequate therapeutic response after specified trials per indication (see individual indications). For RA: inadequate response to at least a 3‑month trial of methotrexate at adequate dosing (e.g., titrated to 20 mg/week) or if methotrexate intolerant/contraindicated, inadequate response/intolerance/contraindication to a 3‑month trial of ≥1 other conventional DMARD
    For PJIA: inadequate response, intolerance, or contraindication to a 3‑month trial of ≥1 conventional DMARD
    For SJIA: inadequate response to at least a 2‑week trial of corticosteroids OR inadequate response to at least a 3‑month trial of methotrexate or leflunomide
    For GCA: inadequate response, intolerance, or contraindication to at least a 3‑month trial of corticosteroids
    For CAR T cell–induced CRS: treatment is for severe or life‑threatening CRS per FDA dosing; CRS use is acute (limited to ≤4 total doses) rather than a standard step‑therapy sequence
    Documentation elementNotes / policy text
    Evidence of prior DMARD failure or intolerance
    RA-specific: documentation of inadequate response to at least a 3‑month trial of methotrexate at adequate dosing (e.g., titrated to 20 mg/week) OR if methotrexate is contraindicated/intolerant, inadequate response/intolerance/contraindication to a 3‑month trial of ≥1 other conventional DMARD (see Appendix lists)
    Record of contraindication or intolerance to alternatives when fewer than two covered alternatives are available
    Baseline infection screening and management documentation: TB screening within 6 months and HBV evaluation or evidence of treatment when indicated; absence of active infection must be documented
    Appendix DMARDClass / example agents
    Conventional DMARDs
    Examples: azathioprine; cyclophosphamide; cyclosporine; hydroxychloroquine; leflunomide; methotrexate; mycophenolate; sulfasalazine
    Biologic DMARDs
    Examples: abatacept; adalimumab; anakinra; brodalumab; certolizumab; etanercept; golimumab; guselkumab; infliximab; ixekizumab; risankizumab; rituximab; sarilumab; secukinumab; spesolimab; tildrakizumab; tocilizumab (Actemra); ustekinumab; vedolizumab
    Targeted synthetic DMARDs
    Listed in appendix as targeted synthetic disease‑modifying agents (see Appendix 1 for full list)

    Coding and Billing

    Referenced drug vial strengths and PA quantity rulesNDC/HCPCS reference (document references Codes table)
    Actemra IV vial sizes referenced (80 mg, 200 mg, 400 mg)Prior-approval quantity entries reference 80 mg, 200 mg, and 400 mg single-dose vials; example: 8 single-dose vials per lifetime for CRS
    HCPCS codesHCPCSCovered
    J3262Injection, tocilizumab, 1 mg.
    Q5133Injection, tocilizumab-bavi (Tofidence), biosimilar, 1 mg.
    Q5135Injection, tocilizumab-aazg (Tyenne), biosimilar, 1 mg.
    ICD-10-CM codes referencedICD-10
    D89.810Acute graft-versus-host disease.
    D89.831 - D89.839Cytokine release syndrome.
    M05.01X- M05.09Felty's syndrome code range.
    M05.09 M05.21X- M05.29Rheumatoid vasculitis with rheumatoid arthritis code range.
    M05.30X- M05.39Rheumatoid heart disease with rheumatoid arthritis code range.
    M05.4X- M05.49Rheumatoid myopathy with rheumatoid arthritis code range.
    M06.00 - M06.0ARheumatoid arthritis without rheumatoid factor code range.
    M06.1Adult-onset Still's disease / related codes referenced.
    M08.00- M08.2AJuvenile rheumatoid arthritis code ranges.
    M31.5 - M31.6Giant cell arteritis code range.
    1–10 of 14
    1/2
    No explicit codes in this partmixed
    No codes listed
    CRS dosing limits
    CRS total dosesTocilizumab for CAR T–cell induced CRS is limited to acute treatment and should not exceed four doses total (continuation/renewal not allowed).
    Age thresholdIndication applies to patients aged ≥2 years for CAR T–cell induced CRS.
    Severity requirementCRS must be severe or life‑threatening to meet indication criteria.
    IV infusion dose cap
    Per‑infusion maximumDo not exceed 800 mg per IV infusion for rheumatoid arthritis (RA) or cytokine release syndrome (CRS).
    Weight‑based dosing context

    Provider Actions and Requirements

    Prior Authorization

    Prior authorization applies with specific quantity and vial limits

    Prior authorization with quantity limits applies for IV tocilizumab; the policy lists indication-specific vial/quantity rules (e.g., Actemra IV single-dose vials in 80 mg, 200 mg, and 400 mg strengths and an example limit of 8 single‑dose vials per lifetime for CRS).

    • Actemra IV single‑dose vial strengths referenced: 80 mg, 200 mg, 400 mg.
    • Example quantity limit for CRS: 8 single‑dose vials per lifetime.
    Prior Authorization

    Prior authorization required for IV tocilizumab

    Prior authorization is required for intravenous tocilizumab (including listed biosimilars) to ensure safe, clinically appropriate, and cost‑effective use as described in the policy.

    Prior Authorization

    Quantity Limits and Site of Care

    Actemra IV vial / quantity rules
    Actemra IV vial quantity limit (CRS)Actemra IV — 80 mg, 200 mg, or 400 mg single‑dose vials; prior‑approval quantity for CRS listed as 8 single‑dose vials per lifetime.
    Vial sizes listedReferenced vial strengths include 80 mg, 200 mg, and 400 mg single‑dose vials for Actemra IV.
    Indication‑specific quantitiesPA quantity entries include indication‑specific vial/quantity rules (e.g., dosing schedules vary by weight and indication).
    IV tocilizumab dose cap
    Per‑infusion capDo not exceed 800 mg per IV infusion for tocilizumab (applies to RA and CRS).
    CRS total dosing constraintCRS dosing is weight‑based (12 mg/kg <30 kg; 8 mg/kg ≥30 kg) with allowance for up to 3 additional doses ≥8 hours apart but total dose cap remains 800 mg.

    Site of Care and Benefit Routing

    Billing Rule

    Bill IV tocilizumab under the medical benefit at appropriate infusion sites

    Infusion of IV tocilizumab should be billed under the medical benefit and is appropriate in infusion center, hospital outpatient, or office settings per the policy's site‑of‑care guidance.

    Billing Rule

    Follow medical‑benefit coding and place‑of‑service guidance for IV administration

    Place‑of‑service and coding guidance indicate IV tocilizumab is billed under the medical benefit; use the HCPCS/ICD/CPT codes referenced in the policy for claims and site‑of‑service reporting.

    • Referenced HCPCS codes: J3262, Q5133, Q5135 (injection codes for tocilizumab and listed biosimilars).

    Biosimilars and Therapeutic Equivalence

    Note

    Actemra IV and listed biosimilars eligible when criteria met

    Intravenous Actemra (tocilizumab) and the listed IV biosimilars (Tofidence, Tyenne) may be considered medically necessary when policy criteria are met.

    Billing Rule

    Biosimilar billing code Q5133 (Tofidence) recognized

    The policy lists HCPCS Q5133 for the biosimilar tocilizumab‑bavi (Tofidence) and treats it equivalently to the reference product for billing when criteria are satisfied.

    • HCPCS Q5133 — Injection, tocilizumab‑bavi (Tofidence), biosimilar, 1 mg.
    Billing Rule

    Biosimilar billing code Q5135 (Tyenne) recognized

    The policy lists HCPCS Q5135 for the biosimilar tocilizumab‑aazg (Tyenne) and treats it equivalently to the reference product for billing when criteria are satisfied.

    Background

    Tocilizumab is an interleukin‑6 (IL‑6) receptor antagonist available in intravenous formulations (Actemra and listed biosimilars) used to treat multiple autoimmune and inflammatory conditions. The policy covers IV tocilizumab for specified FDA‑labeled indications — including adult rheumatoid arthritis, giant cell arteritis, systemic and polyarticular juvenile idiopathic arthritis — and for severe or life‑threatening CAR T cell–induced cytokine release syndrome. The document also references recognized off‑label uses (for example, Castleman’s disease per NCCN) and distinguishes IV (medical/pharmacy routing clarified) from subcutaneous formulations.

    Definitions

    Medical vs. Pharmacy Benefit
    Benefit routing (medical vs pharmacy)Intravenous tocilizumab is billed under the medical benefit; subcutaneous tocilizumab is filled under the pharmacy benefit and is outside the scope of this IV policy.
    Site of careIV tocilizumab is intended for administration in medical settings (infusion center, hospital outpatient, or office) and billed via medical benefit coding.
    COVID‑19 billing noteUse of IV tocilizumab for treatment of COVID‑19 should be billed under the medical benefit as part of inpatient treatment when applicable.
    Biosimilar (policy definition)
    DefinitionBiosimilar: a biological product approved based on data demonstrating it is highly similar to an FDA‑approved reference product with no clinically meaningful differences.
    Examples

    Revision History

    2026-01-01adoption_effective_dateLatest

    Blue Cross of Idaho adoption of policy changes became effective, including addition of a statement about subcutaneous formulation and clarifications to tuberculosis screening.

    2025-09-25policy_replacement

    Policy replaced and changes adopted by Blue Cross of Idaho as noted for a future effective date of 2026-01-01.

    2024-10-31new_policy_added
    Policy Summary
    PayerBluecross Idaho
    PolicyIntravenous Tocilizumab (IV tocilizumab) coverage
    Policy CodePolicy 5.01.502
    Change TypeAdoption with clarifications (TB screening, benefit routing)
    Effective DateJan 1, 2026
    Last ReviewSep 25, 2025
    Next Review DateJan 1, 2026
    Key ActionObtain prior authorization and document TB screening within 6 months, HBV evaluation, and prior therapy failures as required.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation of TreatmentStep Therapy and Prior TreatmentsCoding and BillingProvider Actions and RequirementsQuantity Limits and Site of CareSite of Care and Benefit RoutingBiosimilars and Therapeutic EquivalenceBackgroundDefinitionsRevision History

    See monitoring guidance

    CRS and pediatric SJIA dosing provided as mg/kg (e.g., 12 mg/kg for <30 kg or 8 mg/kg for ≥30 kg) but total per‑infusion dose cap remains 800 mg.
    Recommendation sourcePolicy explicitly states IV tocilizumab doses exceeding 800 mg per infusion are not recommended in RA or CRS patients.
    Unspecified coding notes
    No additional coding notesNo further coding thresholds or exceptions specified in this policy excerpt.
    Appendix referenceSee Appendix 2 for examples of contraindications relevant to alternative therapy selection.
    Coding tablesRefer to the Codes table (HCPCS/ICD-10) in the full policy for billing guidance (J3262, Q5133, Q5135).

    Prior authorization expectation implied by policy adoption and routing

    The policy is a prescription drug policy that requires prior authorization for IV tocilizumab and clarifies benefit routing and management under the medical/pharmacy benefits; requests should be submitted consistent with the policy's authorization process.

    Step Therapy

    Step therapy: document inadequate response to required prior therapies

    Step‑therapy requirements mandate documented inadequate response or intolerance to specified prior therapies before initiating IV tocilizumab — generally failure of required prior agents (e.g., DMARDs or corticosteroids) for the durations specified by indication.

    • RA: inadequate response to a 3‑month trial of methotrexate (or intolerance/contraindication plus failure of ≥1 other conventional DMARD).
    • SJIA: inadequate response to a 2‑week corticosteroid trial or a 3‑month methotrexate/leflunomide trial.
    • PJIA: inadequate response/intolerance/contraindication to a 3‑month trial of ≥1 conventional DMARD.
    Step Therapy

    RA requires prior DMARD trial or documented intolerance

    For rheumatoid arthritis, the policy references prior inadequate response to DMARD therapy (e.g., inadequate response to a 3‑month trial of methotrexate or failure of other conventional DMARDs when methotrexate is not tolerated).

    Note

    DMARDs listed for sequencing / step therapy

    Appendix‑listed DMARDs (conventional, biologic, and targeted synthetic agents) are referenced for sequencing and may be used to document prior therapy failure or intolerance when applying step therapy requirements.

    • Conventional DMARD examples: methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, azathioprine, cyclosporine, mycophenolate, azathioprine.
    • Biologic DMARD examples: abatacept, adalimumab, anakinra, infliximab, rituximab, sarilumab, tocilizumab, etc.
    • Targeted synthetic DMARDs listed in Appendix 1 (see policy appendices).
    Documentation Required

    Required documentation for authorization

    Authorization requests must include documentation of prior inadequate therapeutic response (or documented contraindication/intolerance), TB screening within 6 months, and HBV evaluation or treatment status as applicable.

    • Evidence of trials and durations for prior therapies (e.g., methotrexate 3 months at adequate dosing).
    • TB screening within 6 months prior to initiation or documentation of prior treated latent TB.
    • HBV risk assessment and documentation that HBV has been ruled out or treatment initiated when applicable.
    Documentation Required

    Documentation specifics: infection/TB, hepatic status, and indication justification

    Include infection/TB screening results, baseline hepatic status, and clinical justification for the requested indication (FDA‑approved or NCCN compendium off‑label use) when submitting an authorization.

    • Results of latent TB testing and any TB treatment plan if latent TB is present.
    • Liver function status and documentation excluding active hepatic disease or positive HBV/HCV without management.
    • Statement of FDA‑labeled indication or NCCN‑supported off‑label indication and applicable dosing.
    Documentation Required

    Document benefit routing and TB screening in the authorization record

    Document the benefit routing (medical vs pharmacy) and tuberculosis screening steps in the authorization record; the policy history notes and clarifications about pharmacy benefit routing and TB screening should be reflected in documentation.

    Denial Risk

    Triggers for denial if required screenings, safety, or dosing criteria are absent

    Requests should be denied when required TB or HBV screening is missing, if there is an active infection, if tocilizumab is requested concurrently with another biologic/targeted DMARD, or when dosing/authorization requirements are not met.

    • Missing TB or HBV screening or failure to start TB treatment when latent TB is present.
    • Evidence of active infection or active hepatic disease (including unmanaged HBV/HCV).
    • Concurrent use with other biologic DMARDs, targeted synthetic DMARDs, or immunomodulators.
    • Requests exceeding the IV infusion dose cap (do not exceed 800 mg per infusion) or lacking required prior authorization.
    Denial Risk

    Lack of prior authorization may lead to denial

    Absence of prior authorization for IV tocilizumab may result in denial of coverage; prior authorization is required by this prescription drug policy.

    Denial Risk

    Contraindications and safety exclusions to check before authorizing

    The policy identifies contraindications and safety exclusions that should prompt denial or non‑coverage: active infection (including TB), active hepatic disease or hepatic impairment (including positive HBV/HCV), and use in patients under age 2 for non‑indicated pediatric conditions.

    • Do not initiate in patients with active infections; interrupt therapy until infection is controlled.
    • Treatment is not recommended in patients with active hepatic disease or hepatic impairment, including positive HBV/HCV without appropriate management.
    • Safety and effectiveness not established in children under 2 years for most conditions.
    Billing Rule

    Confirm benefit routing (pharmacy vs medical) to avoid coverage problems

    Ensure to route the product correctly per benefit: the policy clarifies that tocilizumab is to be filled under the pharmacy benefit (where applicable) and IV administration is billed under the medical benefit; incorrect routing may create coverage issues.

    • IV tocilizumab is billed under the medical benefit for infusion settings.
    • Subcutaneous tocilizumab is filled under the pharmacy benefit and subject to pharmacy utilization management.
    RA maintenance dosingRA maintenance dosing referenced elsewhere as weight‑based (commonly 8 mg/kg every 4 weeks) and must adhere to the 800 mg cap per infusion when applicable.
    Billing Rule

    Route dispensing of tocilizumab formulations under the pharmacy benefit when applicable

    Tocilizumab products intended for outpatient dispensing (subcutaneous formulations) should be filled under the pharmacy benefit; the policy notes pharmacy benefit routing for some formulations.

    • HCPCS Q5135 — Injection, tocilizumab‑aazg (Tyenne), biosimilar, 1 mg.
    Biosimilarity has been demonstrated for Tofidence (tocilizumab‑bavi) and Tyenne (tocilizumab‑aazg) for their labeled conditions of use.
    Policy treatmentIV formulations of Actemra and listed biosimilars may be considered medically necessary when coverage criteria are met.
    DMARDs (definition & examples)
    DMARDs definedDMARDs (disease‑modifying antirheumatic drugs) include conventional, biologic, and targeted synthetic agents listed in Appendix 1.
    Conventional DMARD examplesExamples include methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, azathioprine, cyclosporine, mycophenolate, and cyclophosphamide.
    Biologic and targeted examplesBiologic DMARDs (e.g., abatacept, adalimumab, tocilizumab) and targeted synthetics (e.g., tofacitinib, baricitinib) are included for sequencing/step therapy considerations.
    Methotrexate contraindications (examples)
    Methotrexate contraindications — selected examplesContraindications include chronic liver disease (including alcoholic liver disease), breastfeeding, significant blood dyscrasias (e.g., thrombocytopenia, leukopenia, significant anemia), elevated transaminases, hypersensitivity, interstitial pneumonitis or pulmonary fibrosis, myelodysplasia, pregnancy or planning pregnancy, renal impairment, and significant drug interactions.
    Impact on therapy selectionDocumented contraindications to methotrexate may support use of alternative DMARDs or biologic therapy per the policy's prior‑therapy requirements.
    Appendix referenceSee Appendix 2 for the full list of example contraindications to methotrexate used in authorization decisions.

    New policy added to the prescription drug section (policy created and recorded in policy history).